Omniphobic Coating to Prevent Central Line Catheter Infections

Information

  • Research Project
  • 9466069
  • ApplicationId
    9466069
  • Core Project Number
    R43AI136573
  • Full Project Number
    1R43AI136573-01
  • Serial Number
    136573
  • FOA Number
    PA-16-302
  • Sub Project Id
  • Project Start Date
    1/15/2018 - 6 years ago
  • Project End Date
    12/31/2019 - 4 years ago
  • Program Officer Name
    ERNST, NANCY L
  • Budget Start Date
    1/15/2018 - 6 years ago
  • Budget End Date
    12/31/2019 - 4 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
  • Award Notice Date
    1/11/2018 - 6 years ago

Omniphobic Coating to Prevent Central Line Catheter Infections

Central venous catheters (CVLs) provide lifesaving medications, nutrition and laboratory testing for millions of patients a year. As with any medical device, they can become infected (250,000 infections/year in US), increasing patients' mortality and length of hospital stay. The goal of our project is to improve outcomes for patients with peripherally inserted central catheters (PICCs), a common type of CVL, by reducing dangerous complications related to central line-associated bloodstream infections (CLABSI; 10-35 % mortality rate). We believe that stopping adhesion to the surface of the catheter will reduce complications related to infection patients with catheters. Our omniphobic coating stops adhesion of all manner of pathogens (bacteria and fungi) to the surface of medical devices by immobilizing a thin layer of highly inert and biocompatible perfluorinated liquid. In our previous work, we demonstrated that our novel tethered-liquid perfluorocarbon (TLP) coating resists pathogen adhesion in vitro and resists the adhesion of blood clotting components to the surface of medical devices, ultimately resulting in significantly less thrombosis in a challenging in vivo arteriovenous shunt model. In Phase I, we propose the development of a first-in-class TLP-coated PICC catheter that significantly reduces or eliminates catheter-associated infection in patients, potentially resulting shorter hospital stays and less mortality related to hospital-acquired infections. Milestones for Phase I include: 1) showing TLP-coated catheters resist biofouling of many CLABSI-relevant pathogens; 2) demonstrating that the TLP-coated catheters maintain biofouling resistance under extended blood serum flow. If Phase I is successful, in Phase II the TLP-coated catheter will be further evaluated for in vivo biocompatibility in preparation for FDA approval and potentially clinical practice. If successful in this challenging application, the TLP coating could help patients in many other vascular applications and more broadly in medical devices.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    222842
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:222842\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    FREEFLOW MEDICAL DEVICES, LLC
  • Organization Department
  • Organization DUNS
    080388725
  • Organization City
    LANCASTER
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    176015927
  • Organization District
    UNITED STATES